The anti-neprilysin market consists of drugs that inhibit neprilysin enzyme, which degrades various peptides including natriuretic peptides and vasoactive intestinal peptide. Anti-neprilysin drugs are used for various indications including heart failure, hypertension, fibrosis, and renal diseases.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Expanding therapeutic applications of anti-neprilysin drugs is one of the key trends driving the growth of this market. Recent research suggests that inhibition of neprilysin may have potential applications beyond heart failure such as pulmonary hypertension, chronic kidney disease, and fibrotic diseases. Ongoing clinical trials are exploring the efficacy of anti-neprilysin drugs in preventing renal function decline in patients with diabetes as well as in slowing the progression of idiopathic pulmonary fibrosis. The success of these clinical studies may lead to approval of anti-neprilysin drugs for new indications in the coming years, thereby accelerating the market growth.
Segment Analysis
The global Anti-Neprilysin market is dominated by the combination drugs sub-segment. Combination products containing neprilysin inhibitor with other agents like angiotensin receptor blockers show superior efficacy in managing heart failures compared to single agents. This has pushed major drug makers to focus on developing combination therapies rather than single molecule drugs.
Key Takeaways
The global Anti-Neprilysin market is expected to witness high growth over the forecast period. Growing geriatric population who are more prone to develop heart failures will drive the demand. The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
North America currently dominates the market due to high awareness and healthcare spending. However, Asia Pacific region is expected to witness fastest growth due to rising incidents of cardiovascular diseases in counties like China and India. Asia Pacific region is poised to witness fastest growth in the Anti-Neprilysin market during the forecast period. This is attributed to factors like rising geriatric population, growing awareness about treatments and increasing healthcare expenditure in countries like China and India. Presence of generic drug manufacturers will further support the market growth in Asia Pacific region.
Key players related content comprises
Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. BIOPROJET dominates the market with its lead product candidate BEP-NEP for treatment of heart failure. Novartis AG is also conducting clinical trials of its product candidate LCZ696 which is combination of neprilysin inhibitor and angiotensin receptor blocker.
No comments:
Post a Comment